Already a member?
Sign in
Lilly launches phase III trial of targeted cancer agent
Source: Europa Press
Date: 03/09/06
Headline: Lilly launches phase III trial of targeted cancer agent
One of the deadliest and rarest forms of cancer is the focus of a Phase III study initiated by Eli Lilly and Company today. Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of brain cancer.
Date: 03/09/06
Headline: Lilly launches phase III trial of targeted cancer agent
One of the deadliest and rarest forms of cancer is the focus of a Phase III study initiated by Eli Lilly and Company today. Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of brain cancer.
Louise |
Latest page update: made by Louise
, Mar 9 2006, 11:20 AM EST
(about this update
About This Update
Rename
- Louise
No content added or deleted. - complete history) |
|
Keyword tags:
apoptosis
brain cancer
chemotherapy
Colorectal cancer
enzastaurin
glioblastoma
Lung cancer
mantle cell lymphoma
non-Hodgkin's lymphoma
oral agent
Pancreatic cancer
relapse
research
Tumor
More Info: links to this page
|
